— Why it moved
Why CELZ Stock Quintupled Today — June 30, 2026
An FDA green light to expand a Phase 2 back-pain trial took a $4M biotech from 81 cents to $4.72 in one morning — then it gave three-quarters of the move back by the close.
## What moved it A real catalyst for once. The FDA cleared an expansion of the ADAPT Phase 2 trial of CELZ-201 for chronic lower back pain, adding a lower-opioid cohort that's already mostly enrolled, on top of 180-day safety data. The company also disclosed about $4.5M raised through a warrant-exercise inducement, so dilution rode in with the good news.
## The mechanics A $4.4M market cap and a 3.4M-share float that normally trades 127K shares a day. Point real news at that and you get vertical candles. About 185 million shares changed hands.
## Numbers - Cap: ~$4.4M / float: 3.4M - Day volume: ~185M (over 1,000x the 30-day avg) - Prev close: $0.81 → gap +147% - 52w range: $0.79–$6.25
## Where it ended up Stock Pulse flagged it premarket at 8:58 AM, $1.94. It kept running through the opening bell and topped $4.72 at 9:54 AM, up 143% from the alert. The fade started right there and never stopped. It closed at $1.41, 27% below the alert. The move took an hour; the unwind took five.
## Reality check - Peak to close was -70%. Holding the round trip turned a 143% gain into a loss. - That $4.5M warrant inducement means new shares. The rally financed the company, not the holders. - Phase 2 in back pain is years from revenue. This explains the spike, nothing more.